Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rare Disease Integration Into FDA Reviews Will Grow Under PDUFA VI

Executive Summary

Stakeholders wonder about impact of placing orphan drug program staff "into review teams" as part of next iteration of user fee program.


Related Content

US FDA Drug Office Reform: 'Everything' Is On The Table
Patient Advocates Continue To Push US FDA For Central Office
Gottlieb Promotes 'Bottom-Up' Review To Increase FDA Efficiency, Consistency
Sponsors, FDA Reviewers To Get More Flexibility Under New User Fee Program
Orphan Designation Requests To Get Slower US FDA Reviews
Show Me The Money: FDA Recruitment Efforts Challenged By Government Salaries
FDA Orphan Approval Flexibility Remains Steady As Pressure Increases
Regulatory Flexibility Staring Contest: Will Industry Or FDA Blink First?
Rare Disease Products Mostly Approved With Regulatory Flexibility, NORD "Catalog" Finds
PDUFA Commitment Letter Formalizes REMS Standardization Schedule


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts